There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Chemours Company (CC – Research Report) and Clariant AG (CLZNF – Research Report) with bullish sentiments.
Chemours Company (CC)
RBC Capital analyst Arun Viswanathan maintained a Buy rating on Chemours Company on May 17 and set a price target of $48.00. The company’s shares closed last Wednesday at $41.35, close to its 52-week high of $42.85.
According to TipRanks.com, Viswanathan is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chemours Company with a $44.64 average price target, implying a 5.6% upside from current levels. In a report issued on May 2, Alembic Global also maintained a Buy rating on the stock with a $40.00 price target.
Clariant AG (CLZNF)
In a report issued on May 17, Christian Faitz from Kepler Capital maintained a Buy rating on Clariant AG, with a price target of CHF22.00. The company’s shares closed last Monday at $16.80.
According to TipRanks.com, Faitz is ranked #141 out of 7901 analysts.
Currently, the analyst consensus on Clariant AG is a Moderate Buy with an average price target of $20.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CC:
- Wall Street Analysts Are Bullish on Top Financial Picks
- Analysts Are Bullish on Top Technology Stocks: Factset Research (FDS), Stratasys (SSYS)
- BMO Capital Reaffirms Their Buy Rating on Xenia Hotels & Resorts (XHR)
- Barclays Maintains Their Buy Rating on JD (JD)
- Edwards Lifesciences (EW) Gets a Hold Rating from Credit Suisse